on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
Strategic Partnership for Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University announced a partnership on September 26, 2025. The agreement aims to accelerate the development of innovative immunotherapy projects in the fields of oncology, inflammation, and autoimmunity. This partnership combines academic discoveries and industrial expertise to transform research into breakthrough therapies. The alliance strengthens ties in Nantes and expands the national model.
The partners will share their scientific resources to identify and develop promising projects. These projects will benefit from financial support and specific guidance. The partnership aims to capitalize on the strengths of its members to consolidate innovation in immunology in France.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news